CJC-1295 (No DAC)
GROWTH HORMONE SIGNALING RESEARCH
CJC-1295 (No DAC) is being researched as a shorter-acting signal that encourages the body to release more of its own growth hormone. Researchers are interested in how shorter growth-hormone signals may relate to natural GH pulses, recovery, lean tissue and body composition.
WHAT IS CJC-1295 (NO DAC)?
CJC-1295 (No DAC), often called Modified GRF (1-29), is a modified version of part of the body's natural growth hormone-releasing hormone, or GHRH. Its role is to signal the pituitary gland to release growth hormone. Unlike the long-acting CJC-1295 with DAC, the no-DAC form is designed around a much shorter signal rather than a multi-day effect.
WHAT ARE RESEARCHERS STUDYING?
Natural GH Release
GH Pulses
Recovery
Lean Tissue & Body Composition
Researchers are interested in how GHRH-style peptides encourage the pituitary gland to release the body's own growth hormone.
The shorter-acting nature of the no-DAC form has created interest in research involving brief growth-hormone signals rather than prolonged stimulation.
Growth-hormone signaling is studied in connection with normal tissue maintenance and recovery.
Researchers also study how the growth-hormone system relates to lean tissue, fat distribution and overall body composition.
WHY DOES NO DAC MATTER?
The biggest difference is duration. CJC-1295 with DAC was designed to bind to proteins in the blood and remain active for days. CJC-1295 (No DAC) does not have that albumin-binding DAC component, so it is researched as a much shorter-acting GHRH signal.
That makes the two forms different research compounds and means results from long-acting CJC-1295 studies should not automatically be applied to the no-DAC version.
Source: Comparative GHRH Research Analysis
Short
Signal Duration
No DAC
Modified GRF (1-29)
Pulse
Natural growth hormone rhythm
WHERE DOES THE RESEARCH STAND?
The broader GHRH and CJC-1295 research helps explain how this signaling system works, but direct controlled human research specifically on CJC-1295 (No DAC) is limited. The well-known human CJC-1295 studies used the long-acting DAC form.
CJC-1295 (NO DAC) IN SIMPLE TERMS
The simple version: CJC-1295 (No DAC) sends a shorter signal telling the pituitary gland to release growth hormone. Researchers are interested in how that shorter signal interacts with the body's natural growth-hormone rhythm.
CJC-1295 (NO DAC) OVERVIEW
CJC-1295 (No DAC) acts as a brief signal for growth hormone release. Researchers study its effects on natural GH pulses, tissue recovery, and lean body composition, distinguishing it from longer-acting peptide analogs.
GHRH SIGNALING DURATION
CJC-1295 (No DAC) lacks the albumin-binding DAC component, resulting in a much shorter duration of action. Research focuses on how this brief signaling mimics the natural physiological pulses of growth hormone release from the pituitary gland.
NATURAL GH PULSE RESEARCH
Current studies are focused on maintaining the natural rhythm of hormone secretion. By using a shorter-acting compound like Modified GRF (1-29), researchers can observe how the pituitary responds without the continuous stimulation seen in earlier DAC studies.
CURRENT STATUS
While the GHRH signaling system is well understood, specific controlled data for the no-DAC variant remains a primary area of investigation. It is technically distinct from the compounds used in the most commonly cited long-acting human trials.
TESTING & QUALITY
Want to know more about how OSG BioLabs approaches product testing and transparency? Visit our Testing & Quality page.
RELATED RESEARCH
Tesamorelin
Ipamorelin
For research use only. Not for human consumption.